Bank of America Securities analyst Tim Anderson maintained a Sell rating on Regeneron on August 1 and set a price target of $504.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tim Anderson’s rating is based on a combination of factors that suggest caution regarding Regeneron’s stock. Despite the company’s strong second-quarter performance, including impressive revenue and earnings per share (EPS) figures that exceeded expectations, there are concerns about future risks. One significant issue is the potential for faster-than-expected erosion of Eylea, a key product, which could impact future earnings.
Additionally, Regeneron’s high exposure to Medicare Part B poses a risk under the Most Favored Nation (MFN) framework, which could affect pricing and profitability. While the company has a solid research and development track record and promising pipeline readouts expected in the second half of 2025, these positive aspects are overshadowed by the potential challenges. Consequently, Anderson maintains a cautious outlook with a Sell rating, reflecting these uncertainties.